Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and network meta-analysis.

3.2.3 Subgroup analysis for overall survival by PD-L1 expression 3.2.3.1 PD-L1 <1% For SQ-NSCLC (data from 7 trials involving 1, 047 patients and 7 ICI combination regimens), nivolumab plus ipilimumab was associated with prolonged OS compared with atezolizumab plus chemotherapy (HR = 0.56, 95% CrI: 0.32–0.98) and showed a trend toward improved OS compared with pembrolizumab plus chemotherapy (HR = 0.59, 95% CrI: 0.33–1.05); it was ranked as the most effective regimen (SUCRA = 0.83).

also in 53,322 other papers